Allergan Fights to Keep Botox-Making Process Secret From Rival

Company refuses to disclose process in trade secrets fight
Legal dispute is over next-generation of wrinkle treatment

A syringe rests alongside a vial of Allergan Botox, produced by Allergan Inc., in this arranged photograph taken at a skin and beauty clinic in London, U.K., on Monday, Nov. 17, 2014. Actavis Plc agreed to pay about $66 billion for Allergan, a deal that creates a new top 10 drugmaker and ends Valeant Pharmaceuticals International Inc.'s attempt at a hostile takeover of the maker of Botox.Photographer: Jason Alden

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Susan Decker

August 8, 2019 at 8:00 AM UTC

This article is for subscribers only.

Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.

Allergan Plc has gone to great lengths to guard the secret of how it makes Botox, its $2 billion-a-year wrinkle treatment. Metal-enclosed workstations, security guards and private jets are part of the effort.